Controversy remains regarding the optimal antiplatelet regimen in patients with acute coronary syndrome (ACS). This study sought to investigate the efficacy and safety of P2Y12 inhibitor monotherapy compared with conventional dual antiplatelet therapy (DAPT) and aspirin monotherapy in patients with ACS undergoing percutaneous coronary intervention. Data on 4,453 patients were pooled from SMART-DATE and SMART-CHOICE randomized trials. Antiplatelet therapy regimens were categorized as P2Y12 inhibitor monotherapy (P2Y12 inhibitor monotherapy after 3-month DAPT), conventional DAPT (12-month or longer DAPT), and aspirin monotherapy (aspirin monotherapy after 6-month DAPT). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE, a composite of all-cause death, myocardial infarction, and stroke). Inverse-probability of treatment-weighted (IPTW) analysis was performed. At 1 year, patients in the P2Y12 inhibitor monotherapy had a comparable risk of MACCE compared with those in the conventional DAPT (IPTW-adjusted hazard ratio [HR], 0.655; 95% confidence interval [CI] 0.393 to 1.094; p = 0.106), and tended to have a lower risk of MACCE than those in the aspirin monotherapy (IPTW-adjusted HR, 0.606; 95% CI, 0.347 to 1.058; p = 0.078). The adjusted hazard for the Bleeding Academic Research Consortium (BARC) type 2 to 5 bleeding was significantly lower in P2Y12 inhibitor monotherapy than in conventional DAPT (IPTW-adjusted HR, 0.341; 95% CI, 0.190 to 0.614; p < 0.001) and in aspirin monotherapy (IPTW-adjusted HR, 0.359; 95% CI, 0.182 to 0.708; p = 0.003). In conclusion, among patients with ACS undergoing PCI, P2Y12 inhibitor monotherapy after 3-month DAPT reduced risk of bleeding compared with conventional DAPT and aspirin monotherapy after 6-month DAPT without increasing MACCE.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease.Circulation. 2016; 134: e123-e155
- 2018 ESC/EACTS Guidelines on myocardial revascularization.Eur Heart J. 2019; 40: 87-165
- DAPT study investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med. 2014; 371: 2155-2166
- Ischemic versus bleeding outcomes after percutaneous coronary interventions in patients with high bleeding risk.Am J Cardiol. 2020; 125: 1631-1637
- Meta-analysis of dual antiplatelet therapy versus monotherapy ith P2Y12 inhibitors in patients after percutaneous coronary intervention.Am J Cardiol. 2020; 127: 25-29
- SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.Lancet. 2018; 391: 1274-1284
- Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical rial.JAMA. 2019; 321: 2428-2437
- Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions.Circulation. 2007; 115: 2344-2351
- Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium.Circulation. 2011; 123: 2736-2747
- Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.BMJ. 2018; 363: k3793
- Optimizing monotherapy selection, aspirin versus P2Y12 inhibitors, following percutaneous coronary intervention.Am J Cardiol. 2020; 135: 154-165
- Overview of aspirin and platelet biology.Am J Cardiol. 2021; 144: S2-S9
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.Lancet. 2018; 392: 940-949
- Ticagrelor with or without aspirin in high-risk patients after PCI.N Engl J Med. 2019; 381: 2032-2042
- Monotherapy with a P2Y 12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.Lancet. 2020; 395: 1487-1495
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.J Thromb Haemost. 2011; 9: 552-561
- Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.J Thromb Haemost. 2016; 14: 273-281
- Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.Cochrane Database Syst Rev. 2009; 7CD001246
- Risk for major hemorrhages in patients receiving clopidogrel and aspirin compared with aspirin alone after transient ischemic attack or minor ischemic stroke: a secondary analysis of the POINT randomized clinical trial.JAMA Neurol. 2019; 76: 774-782
Published online: May 16, 2021
Received in revised form: March 15, 2021
Received: December 30, 2020
Acknowledgment: This study was supported by unrestricted grants from the Korean Society of Interventional Cardiology (grant number 2013-3), Abbott Vascular, Biotronik, and Boston Scientific.
Clinical Trial Registration: ClinicalTrials.gov Identifier - NCT01701453 and NCT02079194
© 2021 Elsevier Inc. All rights reserved.